Clinical Trial Update: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of difluoromethylornithine, high-dose testosterone, and enzalutamide for metastatic castration-resistant prostate cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Difluoromethylornithine (difluoromethylornithine)
• Enzalutamide (enzalutamide)
• Testosterone (high-dose) (testosterone)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING